CJC-1295 vs Ipamorelin: evidence and differences

CJC-1295 and ipamorelin are two of the most talked-about peptides in the growth hormone (GH) space, and they get lumped together so often that many people assume they do the same thing. They don't. One is a copy of the hormone that tells your pituitary gland to make GH; the other tricks a different receptor into doing the same job. This guide walks through how each works, what the actual human evidence shows, where that evidence is thin or industry-funded, and how the two stack up on safety, legality, and real-world use.

The short version of how they differ

Both peptides aim to raise your body's own growth hormone instead of injecting GH directly. But they pull different levers.

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH), the natural signal from your hypothalamus that tells the pituitary to release GH. Ipamorelin is a growth hormone secretagogue (GHS) that works on the ghrelin receptor, a separate pathway sometimes called the GHRP (growth hormone-releasing peptide) route. Because they hit two different receptors, people often combine them. The idea is that pushing both pathways at once produces a bigger GH pulse than either alone.

That synergy story has biological logic behind it. What it mostly lacks is large, long-term human outcome data. Keep that gap in mind for the rest of this article.

CJC-1295: a long-acting GHRH analog

Mechanism

CJC-1295 is built from the first 29 amino acids of natural GHRH, with a few chemical tweaks to make it last longer in the body. It binds GHRH receptors on the anterior pituitary and increases both the size and duration of natural GH pulses. Critically, it works with your body's own feedback loops rather than overriding them, so GH still comes out in pulses instead of a flat, constant flood.

There are two versions, and the difference matters more than almost anything else in this topic.

• CJC-1295 with DAC (Drug Affinity Complex). The DAC is a chemical group that binds to albumin, a protein in your blood, so the peptide circulates for days instead of minutes. Its estimated half-life in humans is roughly 6 to 8 days.
• CJC-1295 without DAC (also sold as Modified GRF 1-29 or "Mod GRF 1-29"). No albumin anchor, so it clears in minutes to a couple of hours. This is the form most often paired with ipamorelin for short, sharp GH pulses.

When you see "CJC-1295" online, check which version is meant. The two behave like different drugs. The DAC modification was the whole point of the original molecule: natural GHRH falls apart in the bloodstream within minutes, which makes it useless as a once-weekly therapy. By bolting the peptide to albumin, the developers turned a fleeting signal into one that lingers for days. That was clever chemistry. Whether a days-long GH signal is actually good for you is a separate question, and one of the main criticisms of the DAC version.

The criticism goes like this. Your body releases GH in bursts, with quiet valleys in between. Those valleys matter. They let receptors reset and may protect against the downsides of constant GH exposure. A peptide that flattens out the signal into a steady, multi-day elevation arguably fights against that natural rhythm. The no-DAC version and ipamorelin both preserve the burst-and-valley pattern, which is part of why the short-acting combo became more popular than the long-acting CJC-1295 it was named after.

The human evidence

The cleanest human data on CJC-1295 with DAC comes from a Phase 1 study published in 2006 in The Journal of Clinical Endocrinology & Metabolism by Teichman and colleagues. In healthy adults, single subcutaneous doses produced dose-dependent rises in GH and IGF-1. The reported effect was striking on paper: GH rose several-fold and stayed elevated for days, while IGF-1 (a downstream marker of GH activity) climbed and remained up for over a week. With repeated dosing, IGF-1 stayed elevated for weeks. The study concluded the peptide was generally well tolerated at the doses tested. (Teichman et al., 2006, J Clin Endocrinol Metab)

Animal work backs the mechanism. In a GHRH-knockout mouse model, once-daily CJC-1295 normalized growth, confirming the peptide does what a GHRH analog should do. (Alba et al., 2006, Am J Physiol Endocrinol Metab)

Here's the honest part. That JCEM study and a companion trial are essentially the entire body of controlled human evidence, and they measured hormone levels, not health outcomes. They show CJC-1295 raises GH and IGF-1. They do not show it builds muscle, burns fat, improves sleep, heals injuries, or extends healthspan in people. Those are the claims clinics make, and they rest on extrapolation from what GH "should" do, not on trials of CJC-1295 itself.

It gets thinner. CJC-1295 with DAC reached Phase 2 for conditions like growth hormone deficiency and lipodystrophy, then development stopped. One trial participant died. The attending physician attributed the death to pre-existing coronary artery disease rather than the drug, but the program was halted as a precaution and never resumed. No company carried it to approval. So the long-acting version you can buy today was abandoned by its developer before efficacy was ever proven.

This is worth sitting with for a moment, because the marketing rarely mentions it. CJC-1295 is not a peptide that quietly fell through the cracks of a busy pipeline. It is a drug candidate whose development was deliberately stopped, with a death in the trial, by the company that owned it. That doesn't prove the peptide is dangerous — the death was judged unrelated — but it does mean the compound never cleared the bar that every approved drug has to clear. When a clinic tells you CJC-1295 is "well studied," they are usually pointing at a single Phase 1 hormone-level study and ignoring the part where the program died.

There's a measurement nuance, too. The big numbers you see quoted — "GH up 10-fold," "IGF-1 elevated for 11 days" — describe peaks and durations of hormone concentrations in blood. They are real, and they came from a legitimate trial. But a hormone going up in a tube of blood is not the same as a body getting leaner, stronger, or younger. Drug development is littered with compounds that moved a biomarker beautifully and then did nothing for patients. CJC-1295 never got the chance to prove it was different.

Ipamorelin: a selective ghrelin-receptor agonist

Mechanism

Ipamorelin is a small five-amino-acid peptide (a pentapeptide) that mimics ghrelin, the "hunger hormone," at the ghrelin receptor in the pituitary. Activating that receptor triggers a GH pulse. It works on a completely different door than CJC-1295, which is why the two are paired.

The selling point for ipamorelin is selectivity. Older peptides in its class, like GHRP-6 and GHRP-2, also spiked cortisol, prolactin, and appetite. Ipamorelin was the first in its family shown to release GH without meaningfully raising those other hormones.

The human evidence

The foundational study is Raun and colleagues, published in 1998 in the European Journal of Endocrinology, titled "Ipamorelin, the first selective growth hormone secretagogue." In animals (conscious swine and rats), ipamorelin released GH with a potency similar to GHRP-6 but without the rise in ACTH, cortisol, or prolactin seen with the older peptides, even at doses far above what was needed for GH release. (Raun et al., 1998, Eur J Endocrinol)

That selectivity claim is well supported. But notice it comes from animal pharmacology, not a human anti-aging or muscle trial.

The most relevant human data is almost accidental. Ipamorelin was developed as a drug, then tested for postoperative ileus (the temporary gut paralysis after abdominal surgery) because ghrelin-receptor activation also speeds gut motility. A randomized, controlled, double-blind proof-of-concept study in bowel-resection patients found ipamorelin did not significantly beat placebo on the main recovery endpoints, though it was well tolerated. (Beck et al., 2014, Int J Colorectal Dis) The company developing it for that use eventually dropped the program.

So the honest summary for ipamorelin mirrors CJC-1295. Strong evidence it is selective. Decent evidence it is well tolerated in short trials. No controlled human trials showing it improves body composition, recovery, sleep, or aging. The one real efficacy trial in patients was for a gut condition and was negative.

There's an irony in ipamorelin's story that's easy to miss. The peptide was named and characterized as a serious drug candidate by a major pharmaceutical company. It carried strong selectivity data. It got a real, well-designed human trial. And it failed that trial — not because it was unsafe, but because it didn't work for the condition being tested. In drug development, a clean safety profile plus a failed efficacy endpoint usually ends a program. That's exactly what happened. The peptide then found a second life in the wellness market, where the failed efficacy trial is rarely mentioned and the selectivity data gets stretched to cover claims it was never designed to support.

None of this means ipamorelin "doesn't work." It means the thing it's proven to do — release GH selectively, without the cortisol and prolactin baggage of older peptides — is narrower than the thing it's sold to do. Selectivity is a property of the molecule. Fat loss and muscle gain are outcomes in a body, and those haven't been demonstrated for ipamorelin in a controlled human trial.

Head-to-head comparison

Feature	CJC-1295 (with DAC)	CJC-1295 (no DAC / Mod GRF 1-29)	Ipamorelin
Drug class	GHRH analog	GHRH analog	Ghrelin-receptor agonist (GHS)
Receptor target	GHRH receptor	GHRH receptor	Ghrelin receptor (GHSR-1a)
Approx. half-life	~6–8 days	Minutes to ~1–2 hours	~2 hours
GH release pattern	Prolonged, less pulsatile	Sharp short pulse	Sharp short pulse
Selectivity (avoids cortisol/prolactin)	Generally yes	Generally yes	Yes — its main selling point
Best human evidence	Phase 1 PK study (hormone levels only)	Limited; mostly mechanistic	Negative ileus trial + animal selectivity data
Approved by FDA for any use	No	No	No
WADA status	Banned (S2)	Banned (S2)	Banned (S2)

The big practical splits: CJC-1295 with DAC gives a long, steady GH elevation, which some argue blunts natural pulsatility; the no-DAC version and ipamorelin both give brief pulses that better mimic the body's natural rhythm. And ipamorelin is the cleaner of the group on side hormones.

Why people combine them

The standard protocol you'll see is CJC-1295 (no DAC) + ipamorelin dosed together, often before bed. The reasoning:

• CJC-1295 increases the amount of GH available to be released (the GHRH signal).
• Ipamorelin triggers the release and slightly suppresses somatostatin, the brake on GH.
• Hit both at once and you theoretically get a larger, cleaner GH pulse than either alone.

This combination logic is mechanistically reasonable and echoes decades of research showing GHRH plus a GHRP produces additive GH release. But there is no published randomized human trial of the branded combination showing it does anything useful for healthy adults. The synergy is real in the lab. The health benefit in people is assumed.

For more on how clinicians think about combining peptides, see our peptide stacking guide.

Dosing notes (for context, not instruction)

The numbers below reflect protocols used in clinical and research settings. They are not a recommendation. Dosing decisions belong with a licensed clinician.

Item	CJC-1295 with DAC	CJC-1295 no DAC	Ipamorelin
Typical research dose	~1–2 mg per week	~100 mcg per dose	~100–300 mcg per dose
Frequency	1–2x per week	1–3x daily	1–3x daily
Route	Subcutaneous injection	Subcutaneous injection	Subcutaneous injection
Timing notes	Long-acting; timing flexible	Empty stomach, often pre-bed	Empty stomach, often pre-bed

Both peptides come as a freeze-dried powder that must be reconstituted with bacteriostatic water before use. Getting the math right matters; our peptide reconstitution guide covers it. Eating a high-fat or high-carb meal right before dosing can blunt the GH pulse, which is why "empty stomach" shows up so often in protocols.

Safety: what we know and what we don't

Short-term tolerability for both peptides looks reasonable in the small trials that exist. Commonly reported effects across GH-axis peptides include:

• Injection-site redness, itching, or swelling
• Flushing or a head-rush feeling shortly after dosing
• Water retention, tingling, or numbness in hands (carpal-tunnel-type symptoms)
• Increased hunger (more with ghrelin-pathway peptides)
• Headache, fatigue, or lightheadedness

The deeper concern is what raising GH and IGF-1 does over years, because nobody has studied these specific peptides long-term in healthy people. Sustained GH/IGF-1 elevation is biologically linked to insulin resistance, fluid retention, joint pain, and — the most-debated risk — the theoretical promotion of existing cancers, since IGF-1 is a growth signal. None of this is proven for CJC-1295 or ipamorelin at typical doses. But the absence of evidence is not evidence of safety. People with active cancer, uncontrolled diabetes, or pituitary disease are generally steered away from this entire category.

There's also a product-quality problem. Most CJC-1295 and ipamorelin sold for "research" is not pharmaceutical grade, not third-party tested, and not made under FDA oversight. Contamination, wrong dosing, and mislabeling are real risks of the gray market. For a fuller rundown, see peptide therapy side effects and risks.

Honest evidence grading

Here's a sober scorecard. "Strength" reflects how much controlled human evidence backs each claim, not how often you'll hear it repeated.

Claim	CJC-1295	Ipamorelin	Evidence strength
Raises GH and IGF-1 in humans	Yes	Yes (pituitary effect)	Moderate (small Phase 1 / mechanistic data)
Selective; avoids cortisol/prolactin spikes	Generally	Yes	Moderate–strong (mostly animal)
Builds muscle in healthy adults	Not shown	Not shown	Very weak / none
Burns fat in healthy adults	Not shown	Not shown	Very weak / none
Improves sleep or recovery	Not shown	Not shown	Very weak / anecdotal
Safe over years of use	Unknown	Unknown	No long-term data
FDA-approved for any indication	No	No	N/A

Most of the glowing content online comes from clinics and vendors that sell these peptides. That doesn't make the mechanism wrong. It does mean you should treat benefit claims as marketing until a real outcome trial exists.

Legality and sport

Neither CJC-1295 nor ipamorelin is FDA-approved for any use. Both have a tangled compounding history: the FDA placed several peptides, including these two, in a restricted category for bulk-substance compounding, and the regulatory status has shifted repeatedly. The FDA maintains a list of bulk drug substances flagged as potentially risky for compounding. (FDA, Certain Bulk Drug Substances for Use in Compounding) Much of what's sold online is labeled "for research use only," which is a legal workaround, not a stamp of safety.

For athletes, the answer is simple and absolute. Both peptides are banned at all times by the World Anti-Doping Agency under category S2 (peptide hormones, growth factors, and mimetics), which explicitly names CJC-1295 and ipamorelin. (WADA Prohibited List) Using either will fail a drug test in any tested sport.

Who each one is for

• If you want the cleanest side-effect profile on the GHS/ghrelin pathway, ipamorelin is the standard pick. Its selectivity is its best-supported feature.
• If the goal is a sustained GH/IGF-1 elevation, CJC-1295 with DAC delivers that — at the cost of less natural pulsatility and a developer that abandoned it.
• If the goal is a natural-rhythm pulse, the no-DAC CJC-1295 plus ipamorelin combo is the common approach.
• If you compete in tested sport, neither — full stop.
• If you have cancer history, diabetes, or pituitary disease, this whole category warrants caution and a doctor's input.

For how these compare to other GH peptides like sermorelin and tesamorelin, see our overview of growth hormone peptides: sermorelin, ipamorelin, and CJC-1295 and the deeper dive on tesamorelin vs CJC-1295 for body composition.

How they compare to the alternatives

It helps to zoom out. CJC-1295 and ipamorelin are two options in a crowded GH-axis field, and a few of their neighbors actually have approval behind them.

• Tesamorelin is a GHRH analog like CJC-1295, but it crossed the finish line. It's FDA-approved for one specific use — reducing excess belly fat (lipodystrophy) in people with HIV — backed by real outcome trials. That makes it the rare member of this family with proven human efficacy for a defined condition, though only that condition.
• Sermorelin is an older, shorter GHRH fragment. It was once approved as a diagnostic and pediatric GH agent, was later discontinued in that form, and now lives mostly in the compounding world. Weaker and shorter-acting than CJC-1295, but with a longer track record of human use.
• MK-677 (ibutamoren) is an orally active ghrelin-receptor drug — same pathway as ipamorelin, but a pill. It reliably raises GH and IGF-1 in humans and has more long-term human data than ipamorelin, but it also tends to increase appetite, water retention, and sometimes blood sugar.
• Direct GH (somatropin) is the actual hormone, FDA-approved for genuine GH deficiency. It's the most studied option by far and also the most tightly regulated, with the clearest risk profile.

The pattern is consistent. The options with approval (tesamorelin, somatropin) have proven benefits for narrow medical conditions and known risks. The options popular in wellness clinics (CJC-1295, ipamorelin, MK-677) lean on mechanism and short trials. If your goal is general anti-aging or body recomposition in an otherwise healthy adult, none of these has a controlled trial proving it delivers — and the lifestyle basics (sleep, resistance training, protein, fasting before bed) raise natural GH for free, with no needle and no doping ban.

What a realistic GH peptide actually does

Strip away the marketing and here's the defensible claim for both CJC-1295 and ipamorelin: they raise your body's own growth hormone for a few hours after a dose, and they do it more cleanly than the older peptides did. That's it. That's the proven part.

Everything beyond that — leaner waistline, faster injury recovery, deeper sleep, "feeling 30 again" — is downstream theory. GH and IGF-1 are involved in those processes, so it's plausible that nudging them up helps. Plausible is not proven. The companies that could have run those trials either stopped (CJC-1295) or got a negative result on the one human trial they ran (ipamorelin). Until someone funds a real outcome study, a clear-eyed buyer should treat the benefit claims as hypotheses, price in the gray-market quality risk, and remember that the entire category sits outside FDA approval.

Frequently Asked Questions

Is CJC-1295 or ipamorelin stronger?

They aren't directly comparable because they work on different receptors. CJC-1295 with DAC produces a longer, larger overall rise in GH and IGF-1 thanks to its multi-day half-life. Ipamorelin produces a sharper, briefer pulse. In practice they're usually combined rather than ranked, since each amplifies the other's pathway.

Can you take CJC-1295 and ipamorelin together?

Yes — combining CJC-1295 (usually the no-DAC version) with ipamorelin is the most common protocol, because they hit two separate GH-release pathways. The mechanism for synergy is sound, but no published randomized human trial has shown the combination improves body composition, recovery, or aging in healthy adults. The benefit is assumed, not proven.

Are CJC-1295 and ipamorelin FDA-approved?

No. Neither peptide is FDA-approved for any medical use. CJC-1295 stalled in Phase 2 and was discontinued; ipamorelin failed its main human efficacy trial for postoperative ileus. Most products sold are labeled "research use only," which is not the same as being approved or proven safe.

What are the side effects of CJC-1295 and ipamorelin?

Short-term reports include injection-site reactions, flushing, water retention, tingling or numbness in the hands, headache, and increased hunger (more with ipamorelin). The bigger unknown is long-term safety: no controlled studies have tracked these specific peptides in healthy people over years, and sustained GH/IGF-1 elevation carries theoretical risks for blood sugar and cancer growth.

Will CJC-1295 or ipamorelin show up on a drug test?

Yes. Both are banned at all times by WADA under category S2 and are specifically named on the Prohibited List. Any athlete in a tested sport who uses either will test positive. Detection methods for these peptides exist and continue to improve.

---

This article is for educational purposes only and is not medical advice. CJC-1295 and ipamorelin are not FDA-approved for human use. Talk to a licensed healthcare provider before considering any peptide therapy.